MedTrace Logo

7-Days Water-Only Fasting or Ketone Supplementation Trial in Prostate Cancer

NCT06826924 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2026-06-30

No results posted yet for this study

Summary

Activating the immune system to kill cancer cells is a promising therapeutic strategy for some patients with cancer. Unfortunately, current immune-targeting treatments do not work for patients with prostate cancer. In animal models of cancer, fasting can reprogram the body's metabolism and immune cell function to help immune cells kill cancer cells likely by increasing ketosis. The purpose of this study is to determine whether 7 days of water-only fasting or a ketogenic very low-calorie diet or ketone supplementation is safe and feasible for patients with prostate cancer. This will help the investigators develop future studies to test whether incorporating periods of fasting or very low calorie diets or a ketone supplement into treatment plans for prostate cancer can improve outcomes from this disease.

Conditions

Interventions

BEHAVIORAL

Fasting

7 days of water-only fasting

DIETARY_SUPPLEMENT

Ketone Supplementation

7 days of ketone supplementation

Sponsors & Collaborators

  • Abott Lingo Wearables

    collaborator UNKNOWN

  • United States Department of Defense

    collaborator FED

  • Prostate Cancer Foundation

    collaborator OTHER

  • Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

    lead OTHER

Principal Investigators

  • Laura Sena, MD, PhD · SKCCC Johns Hopkins Medical Institution

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-06-03
Primary Completion
2027-06-03
Completion
2027-06-03

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06826924 on ClinicalTrials.gov